Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses.
J Exp Med (1993) 177 (5): 1461–1468.
Currently there are no citedby results. Try again later.
